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Toll-likereceptors(TLRs)areapotenttriggerforinﬂammatoryimmuneresponses.Withouttightregulationtheiractivationcould
lead to pathology, so it is imperative to extend our understanding of the regulatory mechanisms that govern TLR expression and
function. One family of immunoregulatory proteins which can provide a balancing eﬀect on TLR activity are the Leukocyte Ig-like
receptors (LILRs), which act as innate immune receptors for self-proteins. Here we describe the LILR family, their inhibitory eﬀect
onTLRactivityincellsofthemonocyticlineage,theirsignallingpathway,andtheirantimicrobialeﬀectsduringbacterialinfection.
Agents have already been identiﬁed which enhances or inhibits LILR activity raising the future possibility that modulation of LILR
function could be used as a means to modulate TLR activity.
1. Toll-Like Receptor ActivityandAntigen
PresentingCell Phenotype
Toll-like receptors (TLRs) are pattern recognition receptors
with the ability to detect microbial products. They can
provide the initial danger signal required to alert the body to
bacterial or viral infection, playing a pivotal role in the acti-
vation of both innate and adaptive immune responses. TLRs
recognise pathogen-associated molecular patterns (PAMPs),
includinglipopolysaccharide(LPS),amembranecomponent
of gram negative bacteria; lipoproteins, functional proteins
anchoredtothecellmembrane;ﬂagellin,amajorcomponent
of ﬂagellum; heat shock proteins which are highly expressed
during cellular stress and microbial nucleic acids [1, 2].
Ligation of individual or complex TLRs can activate diﬀerent
signalling pathways. Most TLRs signal via MyD88 resulting
in NF-κBo rM A P Ka c t i v a t i o n( Figure 1), ultimately leading
to the transcription of genes associated with antimicro-
bial defence such as inﬂammatory cytokines, costimulation
molecules, MHC, and nitric oxide (NO) [3, 4].
TLRs are widely expressed on immune cells and possess
distinctive functions dependent on cell type and signalling
pathway [5, 15]. We will focus on their eﬀects on dendritic
cells and macrophages, which can act as professional antigen
presenting cells (APCs). The expression proﬁle of TLRs on
APCs varies between subsets (Table 1), which include plas-
macytoid DCs (pDCs), myeloid DCs (mDCs), monocyte-
derived DCs (moDCs), and macrophages. TLR signalling in
these immune cell subsets triggers an activation programme
that includes cytokine secretion; pDCs secrete type I inter-
ferons (IFN-α) which have a fundamental antiviral function
through the recruitment of immune cells and their role in
Tc e l ld i ﬀerentiation [16]. In contrast, mDCs and moDCs
primarily secrete IL-12, a potent proinﬂammatory cytokine
involved in T cell diﬀerentiation and NK cell activation
[17]. Macrophages, which provide an initial antimicrobial
response, also secrete IL-12, NO, and TNF-α which play an
important role in apoptotic cell death and bacterial lysis
[18]. In addition to the production of soluble cytokines and
chemokines, upregulation of various cell surface markers
such as the costimulation molecules and MHC required for
antigen presentation is also observed following TLR activity
[19, 20]. Of these, the best deﬁned costimulation molecules
are CD80, CD86, and B7-H1. Both CD80 and CD86 bind to
CD28 on T cells to provide an activating signal, whereas B7-
H1 binds to PD1 to generate an inhibitory signal [21]. The2 Mediators of Inﬂammation
Table 1: Expression proﬁle of TLR and LILR on diﬀerent APC
subsets: this table depicts the known expression levels of TLRs and
LILR on subsets of APCs. + denotes high expression, −/+d e n o t e s
weak expression, and − is no expression. ? is used where expression
levels are yet to be determined [5–14].
Monocytes Macrophages pDC’s mDC’s moDC’s
TLR1 + + −/++ −/+
TLR2 + + − ++
TLR3 −− − ++
TLR4 + + − ++
TLR5 + + −− −
TLR6 −/++ −/+ −−
TLR7 − ++ + +
TLR8 + + − ++
TLR9 −− ++ +
TLR10 −− − /+ −−
LILRA1 − + −−− /+
LILRA2 + + + + +
LILRA3 + −− − −
LILRA4 −− + −−
LILRA5 + −− − − /+
LILRA6 ? ? ? ? ?
LILRB1 + + + + +
LILRB2 + + + + +
LILRB3 + + + + +
LILRB4 + + + + +
LILRB5 −− /+? −−
type of costimulation molecules upregulated and cytokine
proﬁle secreted by an APC is thought to be determined
by the activation signal given by individual TLRs, and can
determine the nature of the downstream immune response
[20, 22, 23].
Upon migration to the lymph nodes, activated DCs
presentmicrobialantigenstoprimeaspeciﬁcTcellresponse.
MHC class II-restricted antigens are recognised by T helper
(Th) cells, which then secrete proinﬂammatory cytokines
to recruit eﬀector cells and aid in B cell maturation. Th
cell responses are deﬁned by their cytokine secretion proﬁle.
For example, the cytokines IL-12 and IFN-I dominate Th1
responses, resulting in the recruitment of proinﬂammatory
eﬀector cells and the clearance of infection. Th17 cells are
alsoproinﬂammatoryandthroughthesecretionofIL-17and
IL-22 stimulate, for example, the secretion of antimicrobial
proteins from other eﬀector cells. For Th2 responses the
cytokines IL-4 and IL-25 dominate, resulting in inhibition
of proinﬂammatory cytokine secretion and further pro-
liferation. Th1 responses are required for pathogen clear-
ance. However, during excessive immune activation, Th1
responses may damage host tissues, raising the possibility
of pathology or chronic inﬂammatory diseases. In order
to prevent this, populations of Th2 and regulatory T cells
(Tregs) are required, the eﬀects of which regulate the Th1
response [24].
T cell polarisation to either Th1, Th2, or Th17 proﬁle
is dependent on the type of costimulation molecules and
cytokines expressed by the APC [28, 29], which is in
turn determined by TLR signalling proﬁle. In this respect,
signalling through individual or diﬀerent combinations
of TLR may control the nature of the adaptive immune
response towards any given antigen [30]. TLR4, TLR7,
and TLR8 are typically thought to trigger deﬁnitive Th1
responses, whereas TLR2 has been implicated in inducing
Th2 responses. However, recent studies have demonstrated
that simultaneous coligation of TLR2 with other TLRs
alters the signalling proﬁle and ultimately the DC signature
required for T cell polarisation, and may dampen down
TLR4 mediated responses [31]. Coligation with accessory
molecules such as dectin-1 is also thought to play a part in
polarising immune responses [32], and Eisenbarth et al. have
demonstrated that levels of antigen stimulation may impact
on DC signatures, with high levels of LPS triggering a Th1
response, and low levels a Th2 response [31, 33, 34].
As an invading pathogen is likely to possess multiple
PAMPs and trigger several TLRs, any infection would be pre-
dicted to elicit multifaceted T cell responses. Furthermore,
as TLRs are known to complex with other receptors and
recruit adapter molecules involved in signalling cascades,
it is possible that some of these interactions function as
regulatory mechanisms. The mechanisms involved in TLR
regulation are only just becoming clear. Scavenger receptor A
(SRA or CD205) [39], and single Ig IL-1R-related molecule
(SIGIRR)/Toll IL-1R8 have been described as candidate
regulatory proteins [40]. Members of the leukocyte Ig-like
receptor family (LILR, also known as ILTs, LIR, CD85, and
MIR[41–43])havealsobecomeafocusforinvestigationafter
being shown to exert a powerful inhibitory eﬀect on TLR
functions [44]( Figure 2).
2. LILRand TheirMurineEquivalents
(PIRandLILRB4)
LILRs are a family of innate immune receptors that are
predominantly expressed on antigen-presenting cells and B
cells. The eleven members of the human LILRs family are
split into three distinct groups: activating, inhibitory and
soluble. The LILR classed as inhibitory (LILRB1-5) have a
cytoplasmic tail containing 2–4 immunoreceptor tyrosine-
based inhibitory domains (ITIMs). LILRs classed as activat-
ing (LILRA1-2, 4–6) lack any signalling motif, but instead
possess a charged arginine residue which enables association
with the adaptor protein FcεRIγ [45]. To date, this is the
only identiﬁed adaptor molecule shown to associate with
LILR, although it is possible that other adapter molecules
are capable of this association. Signalling is then directed
through the FcεRIγ-associated immnuoreceptors tyrosine-
based activatory domains (ITAMs). Despite this classiﬁca-
tion, the so-called activating group contains receptors with
the ability to exert inhibitory eﬀects, a phenomenon that has
been observed for several ITAM-bearing immune receptors
and is thought to be related to strength of signalling [46].Mediators of Inﬂammation 3
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Figure 1: TLR signalling pathways: All TLRs except TLR3 share a common initial signalling pathway through MyD88 to the
IRAK1/2/4TRAF6 complex. TLR3 uses TRIF to activate the IRAK1/2/4TRAF6 complex. From here, TLR1–6 are able to signal via MAPK
and NEMO to activate API and NF-κB, respectively, and promote transcription of proinﬂammatory cytokines. TLR8 also follows the same
pattern but is only able to signal via NEMO, not MAPK. TLR7/9 are also able to activate NEMO and additionally IKK-α to promote IFN-α
production. In addition to the MAPK and NEMO pathways, TLR3 is also able to signal via TRAF3 to promote IFN-β production [25–27].
LILRs are conserved throughout evolution and to date
homologues have been identiﬁed in rodents [47], chickens
[48], and cattle [49]. In rodents, LILR equivalents are known
as paired immunoglobulin-like receptors, a family that
contains multiple activating receptors (PIR-A) but only one
inhibitory receptor, PIR-B [47, 50–52]. PIRs were classiﬁed
as LILR homologues due to their similarities in genetic
sequence and location, expression proﬁle, structure, and
function [53–55]. They have since proved to be an eﬀective
tool to examine the role of these receptors [51]. A further
murine homologue, LILRB4 was previously known as gp49B
[56].
Similar to TLRs, LILR expression varies between APC
subsets (Table 1). MDC and moDCs express LILRA2,
LILRB1, LILRB3, and LILRB4, whereas pDCs express
LILRA4, LILRB1, and LILRB4 [6, 57]. LILRB1, LILRB4 and
LILRA4expressionisdecreaseduponDCmaturation[6,58].
Individual receptors exert their regulatory function in a
varietyofways.Upregulationand/orcross-linkingofLILRB2
inhibits the upregulation of co-stimulatory molecules on
APCs, resulting in T cell anergy [59]. In contrast, signalling
through LILRA2 inhibits the upregulation of CD1b, HLA-
DR, CD40, CD80, CD86 and, CD206, and prevents eﬀective
T cell activation and proliferation [60]. Unlike LILRB2,
which inhibits APC eﬀector functions by downregulating
costimulation molecules, LILRB4 has recently been shown to
inhibit APC response to bacterial infection by upregulating
IL-10 production and subsequently downregulating IL-8
secretion. Ligation of LILRB4 does not appear to aﬀect
the expression of costimulation molecules [61]. However,4 Mediators of Inﬂammation
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Figure 2: Possible pathways for LILR regulation of Toll-Like Receptor Signalling Pathways: There are several possible mechanisms of
inhibition LILR receptors may employ to regulate TLRs. SHP-1 has been shown to associate with IRAK1 and inhibit further downstream
signalling.Similarly,SHP-2andSHIPhavebeenshowntoinhibitdownstreamsignallingofTBK-1andPI3K,respectively,therebydampening
down the production of proinﬂammatory mediators [35–38].
Lu et al., demonstrated that LILRB4 was able to inhibit TNF-
α release via inhibition of FcγRI signalling [62], in line
with the ability of murine LILRB4 to inhibit inﬂammatory
cytokine production [63]. LILRB4 has also been shown to
be highly expressed in patients with malignancy, and this
receptor is thought to play a critical role in the induction
of tolerance. However, it is not known whether LILRB4
expressiononmalignantcellsisinducedbyregulatoryTcells,





B, and their corresponding human homologues LILRB1 and
LILRB3 have been shown to bind bacteria including E. coli,
H. pylori, and S. aureus [64]. The bacterial ligand(s) involved
in this interaction are yet to be determined and individual
receptors vary in their bacterial speciﬁcity. However, the
most thoroughly characterised ligand for LILR is MHC class
I (MHC-I). Unlike other MHC-I-speciﬁc receptors, LILRs
show a broad speciﬁcity for classical and nonclassical forms
of MHC-I; LILRB1 and LILRB2 bind all classical MHC-I
as well as some nonclassical alleles [65]. LILRB2 has been
shown to bind CD1d, which is an MHC-I-like molecule
able to present nonprotein antigens to T cells [66]. CD1d is
usually recognised by the TCR receptor of NKT cells, which
results in the activation of proinﬂammatory eﬀector cells
and target cell lysis. LILR modulation of CD1d activity may
therefore be of particular importance in bacterial infections,Mediators of Inﬂammation 5
which can result in an overaccumulation of lipids in the
infected cell [66, 67].
Inhibitory LILRs have been shown to exhibit their
functions both independently and in association with acti-
vating receptors such as TLRs. Inhibitory LILR carry their
own signalling motifs, varying from 2 to 4 ITIMs in
their cytoplasmic tail. Variation in the number of ITIM
domains has been proposed to result in signal ampliﬁcation
or the recruitment of alternative signalling molecules [7].
Upon activation phosphorylated tyrosines within an ITIM
become docking sites for either the Src homology 2 domain-
containing phosphatase 1 (SHP-1) or SHP-2, or the SH2
domain-containing 5  inositol phosphatise (SHIP) [58].
These phosphatases then dephosphorylate key molecules
further downstream in the cascade or those involved in the
ITAM signalling of activating receptors, with consequent
inhibitoryeﬀects[7].SHP-2isparticularlyimportantinboth
positive and negative regulation of cellular diﬀerentiation
[58]. Although yet to be fully deﬁned, these signalling
patterns are likely to be found mimicked in the modulation
of TLR activation [68, 69].
As mentioned previously, activating LILR has a positively
charged arginine residue within the cytoplasmic domain,
which enables association with adapter proteins, such as
FcεRIγ. When activated, tyrosine molecules in the ITAM
domain of FcεRIγ are phosphorylated by protein tyrosine
kinases of the Src family kinases, creating binding sites
for further signalling molecules, such as zap70 or syc [7].
The recruited signalling molecules may diﬀer depending
on cell type, and therefore LILRs may be involved in
modulating a wide range of intracellular signalling pathways
[70].
3.1. LILR-Mediated Control of TLR Functions. LILR-
mediated control of TLR activity has been documented
for several diﬀerent bacterial infections. In the case of S.
aureus, LILR and PIR-B receptors can bind the pathogen in
conjunction with TLR2 and trigger the release of inhibitory
cytokines such as IL-10 [64]. Inhibition of TLR2 signalling
by PIR-B was conﬁrmed in a study of PIR-B
−/− mice, where
an excessive Th2 response was observed, coupled with
impaired DC maturation. This inhibition of DC maturation
was thought to arise from the absence of PIR-B regulation
of a common signalling pathway used by IL-3, IL-5, and
GM-CSF [71].
Evidence of a role for LILR (and their murine homo-
logues) providing a counterbalance to TLR activity is most
strikingly illustrated by the high mortality rate of Salmonella
infection for mice lacking the inhibitory receptor PIR-B
[72, 73]. Interestingly, instead of the exacerbated immune
responses that might have been expected in the absence of an
inhibitory receptor, PIR-B-deﬁcient mice were actually more
susceptible to Salmonella infection, caused by a decrease in
phagosomal oxidant production, necessary for bacterial lysis
within lysosomes [72].
Mycobacterium leprae infection can result in tuberculoid
(T-lep) or lepromatous leprosy (L-lep). Patients with T-lep
typically display a localised form of disease, with eﬀective
bacterial clearance. In L-lep, patients suﬀer from dissemi-
nated disease, with large numbers of bacilli. Although the
factors that inﬂuence disease course are currently unknown,
polymorphisms in TLR2/1 are thought to play a role [60]. In
a study by Bleharski et al., gene expression analysis identiﬁed
an up to 5.4-fold overexpression of LILRA2 in skin lesions
of L-lep, compared to T-lep [73]. Infected macrophages
stimulated with LILRA2 ligands showed a 40% reduction in
antimicrobial responses, indicating that LILRA2 also inhibits
antimicrobial functions in macrophages [73]. Furthermore,
ligation of LILRA2 considerably reduced IL-12 production
by TLRs, skewing cytokine activity towards a Th2-biased
response. This is important as the immune response in T-lep
lesions (where infection is generally contained then cleared)
is Th1-biased, whereas L-lep with its higher bacterial loads
and disseminated infection is Th2-biased. Therefore, it is
possible that the overexpression of LILRA2 in L-lep results
in an inadequate Th2-biased immune response and a more
severe form of disease [60]. LILRB5, LILRB3, and LILRA3
are also overexpressed in L-lep patient lesions, although their
relevance in infection has yet to be determined [70].
Signalling through diﬀerent TLRs has been shown to
result in diﬀerent LILR expression proﬁles [6, 61, 74]. In
human cells the inhibitory receptors LILRB2 and LILRB4
were upregulated following Salmonella infection, an eﬀect
which appears to be mediated largely by LPS recognition, as
activation of LILRB4 also occurred by both heat-inactivated
Salmonella and Salmonella LPS [61]. In this respect, LILRB4
may play an important role in TLR4 regulation. Similar
relationships exist for other LILR and TLR: LILRA4 has been
shown to regulate TLR7/9 activity in pDC and LILRA2 has
been shown to inhibit TLR4-mediated activity.
In viral infections, the pDC subset plays an important
role in mediating antiviral immunity upon activation by
pathogenic ligands. TLR7/9, together with TLR3 and TLR8
are localised in endosomal/lysosomal compartments [75],
where their activation leads to the production of TNF-
α and IFN-I, a group of potent antiviral cytokines. The
newly-characterised receptor LILRA4 is expressed only on
pDCs, where it appears to play an important role in the
control of their activity in response to viral TLR stimulation.
Following recognition of its ligand, tetherin (also known
as BST2), LILRA4 downregulates TLR7 and TLR9-mediated
production of IFN-α and TNF-α, and decreases calcium
mobilisation [76]. However, LILRA4 activity does not aﬀect
the maturation of the cell, as upregulation of CD80/CD86
is still observed. LILRA4 is also able to inhibit TLR7
and TLR9 signalling after prior antigen stimulation, but
is selectively downregulated upon pDC activation [76, 77].
Similarly in murine models, PIR-B has been shown to
inhibitTLR9-mediatedsignallingviaBrutonstyrosinekinase




Given the potent eﬀects of LILR on TLR activity, there
is the potential in future to use these receptors as a6 Mediators of Inﬂammation
tool for therapeutic modulation of TLR signalling. For
example, inhibitory LILR could be triggered by their highest
aﬃnity self-ligand, HLA-G [70]. This nonclassical MHC-I
allele has a restricted distribution of expression, limited to
placental trophoblast cells and thymus epithelial cells, but is
overexpressed in certain pathologies including nonrejected
allografts, HIV infection, and tumours [79, 80]. HLA-G
expression is known to trigger the upregulation of LILR
[80]. HLA-G also has a natural tendency to form disulphide-
bonded dimers which in turn enhance binding to LILRB1
and LILRB2, resulting in enhanced immunosuppressive
eﬀects [81]. Thus, there is therapeutic potential for recombi-
nant HLA-G to be used to downregulate TLR eﬀects through
enhancing LILR activity.
Enhancing LILR expression would be expected to exert a
further dampening eﬀect on TLR activity. Expression levels
of LILR can also be enhanced by certain agents; Vitamin
D3, Dexamethasone, and niﬂumic acid have been shown
to up-regulate the expression of LILRB2 and LILRB4 on
DCs, which is seen with an accompanying increase in IL-
10 secretion and Treg diﬀerentiation. Although the exact
mechanisms involved in tolerance induction in these studies
are yet to be fully elucidated, high expression of LILRB4 is
thought to be strongly associated with inhibition of NF-κB
activation [82, 83]. Recently a study examining the eﬀects of
1,25(OH)2D3 on DCs demonstrated that this agent is able
to up-regulate LILRB4 on moDCs and mDCs but not pDCs.
This may be due to the fact that the normal expression levels
of LILRB4 are markedly higher on pDCs than mDCs [84].
Furthertothis,theIDOactivityintryptophan(trp)deﬁcient
cells was used in a study recently to deﬁne mechanisms
of DC tolerance and induction of Tregs. Brenk et al.
found that upon DC tolerisation, high levels of LILRB3
and LILRB4 were upregulated. However, replacement of
trp was unable to reverse the tolerogenic conditions, and
D C sc o n t i n u e dt os t i m u l a t eTc e l l st od i ﬀerentiate into
a regulatory phenotype. Furthermore, only by using anti-
LILRB4 antibodies were they able to restore any function to
the DCs and subsequently the T cells. The authors predict
that DC regulation induced in this manner may aﬀect the
epigentics of foxP3 gene transcription and provide antigen-
speciﬁc Treg cells, therefore providing a mechanism open to
therapeutic manipulation [85].
Given the powerful inhibitory nature of LILR, it may
be possible to modulate the expression of these receptors
prior to or in conjunction with chemotherapies in order to
enhancetreatmenteﬃcacy.Blockingtheinhibitoryfunctions
of LILR has been demonstrated recently in a study by Morel
and Bell´ on, in which amoxicillin was shown to have the
ability to interfere with LILRB1 recognition of MHC class I
on NK cells, a ﬁnding which could potentially have a large
impact on tumour immunology and therapeutics [86]. With
further research, the bacterial interaction with LILR will
most likely prove fundamental in deﬁning regulatory path-
ways involved in TLR pathogen responses. As more ligands
are discovered for these inhibitory receptors, the potential
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